A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.
Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching PA, Sinn BV, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young BM, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S.
Karn T, et al. Among authors: van mackelenbergh m.
Clin Cancer Res. 2020 Apr 15;26(8):1896-1904. doi: 10.1158/1078-0432.CCR-19-1954. Epub 2020 Jan 13.
Clin Cancer Res. 2020.
PMID: 31932495
Clinical Trial.